Wound Heal
Conditions
Brief summary
Evaluate the performance and safety of the use of Hyalo4 Skin Gel in terms of wound management
Detailed description
Ths clinical investigation study is to evaluate the performance and safety of Hyalo4 Skin Gel in the management of acute or chronic wounds of different etiology, according to the indication for use, the prescriptions of the clinicians and the standard procedures of the sites. A maximum of 7 Visits will be performed, with the first 4 visits performed over a 4-weeks period for each patient and the last visit after 8 weeks from the first visit. The schedule treatment will consist of daily medication changes, according to the instruction for use and the clinical practice.
Interventions
DEVICEHyalo4 Skin Gel
The evaluation of performance and safety of Hyalo4 Skin Gel in the amelioration of bed wound appearance after 14 days of treatment.
Sponsors
Fidia Farmaceutici s.p.a.
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Signed written informed consent. 2. Male or female ≥18 years. 3. Patients selected to be treated with Hyalo4 Skin Gel. 4. Patients with wound of the following etiology: first and second degree burns; surgical wounds; vascular ulcers; metabolic ulcers; pressure ulcers. 5. Patients followed on an outpatient or home basis. 6. Wound area ≥ 10 cm2 and ≤ 100 cm2
Exclusion criteria
1. Patients \< 18 years. 2. Patients with acute or chronic infected lesions. 3. Hospitalized patients. 4. Women who are pregnant or breastfeeding or women who could become pregnant and are not using effective contraception. 5. Patients with acute or chronic lesions at high risk of infection, presenting at least one of the following criteria: * Stalled wound, without any clinical sign of healing progression * Immune system disorders * Protein-energy malnutrition * Alcohol, smoking and drug abuse (50ml of spirit, 0,5L of wine and 10 cigarettes/day) * Conditions associated with hypoxia and/or poor tissue perfusion * Corticosteroid, cytotoxic or immunosuppressive therapy. 6. Subjects unable to understand informed consent or having a high probability of non-compliance with the study procedures and or non-completion of the study according to investigator's judgement
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Performance of Hyalo4 Skin Gel treatment | 14 days | The outcome will be measured as percentage of patients showing positive change in at least one of the following parameters: amelioration of wound tissue type (necrotic, slough, granulation tissue, epithelial tissue, closed), decrease of exudate amount (dry, moist, slightly exuding, heavily exuding, wet) and amelioration of exudate type (bloody, bloody/purulent, clear, murky, purulent, serous). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| EQ5D-Patient's quality of life | 56 days | Patient's quality of life assessment will be evaluated as a change from baseline to 56 days after the start of treatment, through administration of EuroQoL-5D (EQ-5D). |
| Performance of treatment | 7,21,28,42 and 56 days | The performance of Hyalo4 Skin Gel will be evaluated from baseline to 7, 21, 28, 42 and 56 days as amelioration of wound bed appearance in terms of: type of wound bed tissue and exudate quantity and quality. |
| Safety and Tollerability | 56 days | The safety and tolerability of Hyalo4 Skin Gel will be assessed throughout all the visits by investigating local and expected adverse events, as consequence of the product application and any other adverse event occurred during the study. |
Countries
Slovakia
Contacts
Primary ContactNiocola Giordan
Outcome results
None listed